

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/633,762	08/04/2003	Fred Hassan	00860.US1	5124
28523 7590 09/04/2007 PFIZER INC.		EXAM	EXAMINER	
	ARTMENT, MS8260-	1611	HUI, SAN MING R	
EASTERN POINT ROAD GROTON, CT 06340			ART UNIT	PAPER NUMBER
		•	1617	
			MAIL DATE	DELIVERY MODE
•		•	09/04/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
Office Action Summers	10/633,762	HASSAN, FRED			
Office Action Summary	Examiner	Aṛt Unit			
·	San-ming Hui	1617			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any. earned patent term adjustment. See 37 CFR 1.704(b).					
Status	•	•			
1)⊠ Responsive to communication(s) filed on <u>23 M</u>	Responsive to communication(s) filed on 23 May 2007				
_					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
<u></u>					
4) Claim(s) <u>1-18</u> is/are pending in the application.					
4a) Of the above claim(s) 10-15 is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-9 and 16-18</u> is/are rejected. 7)□ Claim(s) is/are objected to					
8) Claim(s) are subject to restriction and/o	r election requirement	:			
Application Papers					
9) The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
<u> </u>	1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
		•			
Attach mant/s)		· ·			
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date					
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal F				
Paper No(s)/Mail Date 6) Other:					

Art Unit: 1617

DETAILED ACTION

Applicant' amendments filed May 23, 2007 have been entered.

Claims 1-18 are pending. Claims 10-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on November 29, 2006.

The outstanding rejection under 35 USC 112, first paragraph is withdrawn in view of the amendments filed May 23, 2007.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 1617

Claims 1-9 and 16-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scrip from IDS filed 1/16/2007 in view of Holm and Spencer, reference AP from IDS filed 2/23/2004.

Scrip teaches low dose of certain new antidepressants such as noradrenaline reuptake inhibitors as useful in treating hot flashes in postmenopausal women with breast cancer history who cannot take estrogen-based products (See paragraph 1 and 2).

Scrip does not expressly teach the employment of reboxetine to treat hot flashes.

Holm and Spencer teaches reboxetine as noradrenaline reuptake inhibitor (See the abstract). Holm and Spencer teaches that the dosage of reboxetine as 4mg daily as starting low dose and titrate up to 6mg daily (see page 80, col. 1, Dosage and Administration Section).

It would have been obvious to one of ordinary skill in the art at the time of invention to employ reboxetine in a method of treating hot flashes.

One of ordinary skill in the art would have been motivated to employ reboxetine in a method of treating hot flashes. It is known that low-dose noradrenaline reuptake inhibitors as effective in treating hot flashes. Therefore, employing any known noradrenaline reuptake inhibitors, such as reboxetine, in a low-dose would be reasonably expected to be useful and effective in treating hot flashes.

Response to Arguments

Application/Control Number: 10/633,762

Art Unit: 1617

Applicant's arguments filed May 23, 2007 averring the cited prior art's failure to teach reboxetine since Scrip only teaches either a serotonin reuptake inhibitor (SRI) (e.g. fluoxetine and paroxetine) or a serotonin and norepinephrine reuptake inhibitor, have been fully considered but they are not persuasive. The Examiner notes that Scrip teaches the use of low dose serotonin **or** noradrenaline reuptake inhibitors can provide relief from hot flushes in women (emphasis added) although only venlaflaxine is exemplified. Therefore, possessing the teachings of the cited prior art, one of ordinary skill in the art would have been motivated to employ any known noradrenaline reuptake inhibitors, such as reboxetine, in a low-dose for the relief of hot flushes, absent evidence to the contrary.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

San-ming Hyll Primary Examiner

Art Unit 1617